About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, January 22nd, 2018

The QualityStocks
Daily Stock List


Freedom Leaf, Inc. (FRLF)

SmallCapVoice, Promotion Stock Secrets, CFN Media Group, and StocksToBuyNow reported on Freedom Leaf, Inc. (FRLF), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Freedom Leaf, Inc. (The Marijuana Legalization Company™) is a leading go-to resource in the cannabis, medical marijuana, and industrial hemp industry. The Company engages in mergers and acquisitions (M&A’s) in the marijuana industry. This includes incubation/acceleration and spin offs of new marijuana/hemp related companies. Freedom Leaf does not handle, grow, sell, or disperse marijuana. Freedom Leaf is headquartered in Las Vegas, Nevada. Leafceuticals, Inc. is a wholly-owned division of Freedom Leaf.

The Company targets acquisitions of high growth and niche companies. Its strategy is to identify select technology companies and companies that are involved in cannabis and industrial hemp genetics, intellectual property (IP), bioscience, nutraceutical, and pharmaceutical product development.

Freedom Leaf earlier acquired LaMarihuana.com. This is the Spanish Speaking community's top cannabis website. As part of this acquisition, Freedom Leaf acquired www.Marihuana-Medicinal.com. This is the largest Medical Cannabis information website in Spanish.

Freedom Leaf’s flagship publication is Freedom Leaf Magazine, The Good News in Marijuana Reform. Freedom Leaf produces a portfolio of news, print, and digital multi-media verticals, websites, and web advertising, for the ever-changing and developing cannabis, medical marijuana, as well as industrial hemp industry.

The content Freedom Leaf produces and curates primarily attracts industry professionals. This includes lawyers, legislators, activists, entrepreneurs, and people active in the business of cannabis and industrial hemp. The Freedom Leaf enterprise has become a leader in media production and distribution for the cannabis/hemp industry.

Hempology® is Freedom Leaf’s exclusively branded product line. Hempology® is now vertically integrated from seed to consumer, processing CBD and a comprehensive spectrum of whole-hemp extracts for the entourage-effect.

Freedom Leaf reported in August of 2017 significant developments in its Spanish acquisition, Green Market Europe (GME), in combination with University Miguel Hernandez in Elche, Spain. Freedom Leaf and GME signed a Letter of Intent (LOI) for Freedom Leaf to acquire 100 percent of GME's IP, projects, and assets.

Freedom Leaf agreed to expand two additional growing operations globally before the end of 2019 to maximize the skills and the potential of staff.

Last month, Freedom Leaf announced that it entered into a purchase agreement for organically grown hemp, which will permit it to legally extract Industrial Hemp in Nevada under NV SB396 and the 2014 US Farm Bill.

Leafceuticals, the wholly-owned division of Freedom Leaf, entered into an initial purchase agreement with hemp producer Harris Farms, Ltd, of Pahrump, Nevada to fully extract the wide array of phytocannabinoids (CBD), terpenes and other valuable byproducts from 600 pounds of nurtured Hemp flower that has been grown under the NV Department of Agricultures Industrial Hemp Pilot project.

Earlier in January, Freedom Leaf report that it fully acquired 100 percent of Green Market Europe S.L. (GME). GME is a Spanish producer of hemp products. Its facilities include a 21,000 sq. ft. light deprivation greenhouse, a 43,000 sq. ft. indoor growing research facility, and more than 200 acres of outdoor production space.

Freedom Leaf, Inc. (FRLF), closed Monday's trading session at $0.146, up 54.33%, on 5,615,872 volume with 567 trades. The average volume for the last 60 days is 1,146,457 and the stock's 52-week low/high is $0.0265/$0.14.

BioSolar, Inc. (BSRC)

Stock Roach, Stock Preacher, Penny Stock Rumble, Beacon Equity Research, TheLightningPicks, HoleinOneStocks.net, Investor News Source, StockHideout, TopPennyStockMovers, PennyTrader Publisher, OTCPicks, MicroStockProfit, and BioSolar Newsletter reported earlier on BioSolar, Inc. (BSRC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

BioSolar, Inc. is developing an inventive technology to increase the storage capacity, reduce the cost, and extend the life of lithium-ion batteries. The Company initially focused its development effort on high capacity cathode materials since most of contemporary Li-ion batteries are "cathode limited." With the objective of creating BioSolar’s next generation super battery technology, the Company is presently investigating high capacity anode materials. BioSolar has its corporate headquarters in Santa Clarita, California.

BioSolar has its BioBackSheet®. The Company is the leading commercial provider of bio-based solar panel backsheets. A backsheet is a required insulating film in all solar photovoltaic panels. Its primary purpose is to protect the solar panel components, specifically the solar cells and wires. The Company’s BioBackSheet® is the only commercially available Underwriters Laboratory (UL) certified bio-based backsheet.

The Company is developing BioSolar supercapacitors. This is technology for lessening the cost of storing the energy of the sun. BioSolar co-owns the patent-application for this supercapacitor technology with the University of California at Santa Barbara (UCSB). The Company is funding a sponsored research program to advance its development.

Through integrating BioSolar supercapacitors as the high power front-end to battery banks, with fewer battery banks than would usually be required, daytime solar energy can be rapidly and cost-effectively stored for night-time use at a significantly lower cost. The technology will enable solar energy systems users to decrease their dependence or go completely off the electric utility power grid.

BioSolar’s management believes that use of its silicon-metal (Si-M) anode materials, currently under development, can help reduce the cost of lithium-ion batteries. The expectation is that the Company’s Si-M anode material will be much less expensive than that of the benchmark silicon-carbon anode material that is the key cost issue typically associated with battery technology. BioSolar’s belief is that its strategy of pursuing anode material advancements to support next-generation lithium-ion batteries can play an important role within the electric vehicle sector, and the broader energy storage technology industry.

In 2017, BioSolar successfully completed the laboratory phase of its silicon nanocomposite alloy anode material technology development. BioSolar (with data that suggests its technology can attain considerably higher capacity at decreased costs,) began the process of identifying potential strategic partners for commercial development of its proprietary battery technology.

In addition, BioSolar signed a Joint Development Agreement with Top Battery, a foremost lithium-ion battery manufacturer. Furthermore, BioSolar developed a proprietary additive technology. This technology has the potential to improve all kinds of silicon anode materials. This includes Si carbon composite, Si oxide type, as well as Si alloys.

Furthermore, the Company demonstrated that its additive technology exhibited substantial improvement in battery capacity and capacity retention when applied to Si anodes made from Si micro-particles, a form of raw silicon more cost effective than Si nano-particles.

BioSolar, Inc. (BSRC), closed Monday's trading session at $0.0326, up 11.52%, on 93,790 volume with 10 trades. The average volume for the last 60 days is 137,157 and the stock's 52-week low/high is $0.025/$0.10.

iAnthus Capital Holdings, Inc. (ITHUF)

Stockhouse, MarketWatch, InvestorsHub, Daily Marijuana Observer, and OTC Markets reported on iAnthus Capital Holdings, Inc. (ITHUF), and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.

iAnthus Capital Holdings, Inc. is a provider of capital investment and management services to licensed cannabis cultivators, processors, and dispensaries throughout the United States. The Company, via its 100 percent owned subsidiary, iAnthus Capital Management, LLC, delivers a complete solution for financing and managing these enterprises. iAnthus supports a varied portfolio of cannabis industry investments. iAnthus Capital Holdings has its head office in New York, New York. The Company also has a Toronto, Ontario office.

Entrepreneurs with decades of experience in investment banking, corporate finance, law, and healthcare services founded iAnthus Capital Holdings. iAnthus remains hands-on with its investments. It works with its partners to optimize opportunities, overcome hurdles, and maximize value.

iAnthus owns, operates, and partners with licensed cannabis operations across the United States. It provides a unique combination of capital and practical operating and management expertise.

The Company creates agreements that establish valuable partnerships. It has developed strategic partnerships with best-in-class industry-sector leaders in dispensary operations, commercial-scale cannabis cultivation, regulatory law, and the science of cannabis product formulation and testing.

iAnthus applies meticulous analysis to ascertain the very best business prospects in each market throughout the U.S. The Company’s current portfolio includes Grassroots Vermont; Mayflower Medicinals, Inc.; Organix, Breckenridge Colorado; and R. Greenleaf Organics.

Earlier this month, iAnthus Capital Holdings announced that Mayflower Medicinals received its final certificate of registration (FCR) and certificate of occupancy (CO) from Massachusetts regulators and local officials on December 28, 2017 to start cannabis cultivation and production operations at its facility in Holliston, Massachusetts.

Mayflower Medicinals is a non-profit Massachusetts corporation. It has received two provisional licenses to operate Registered Marijuana Dispensaries (RMDs) in Massachusetts, with a third RMD application pending before the Massachusetts Department of Public Health (DPH).

Furthermore, iAnthus announced the completion of its acquisition of 80 percent of Pilgrim Rock Management, LLC. Pilgrim Rock is an affiliated management and services company. It will provide intellectual property (IP) licensing, professional and management services, real estate and equipment leasing, and certain other services to Mayflower Medicinals, pursuant to a services agreement between Pilgrim Rock and Mayflower effective as of January 1, 2018.

Last week, iAnthus Capital Holdings announced it acquired by way of merger and acquisition transactions substantially all of the assets of GrowHealthy Holdings, LLC and certain related subsidiaries. The Acquisition completes iAnthus Capital’s full-scale entry into the fast expanding Florida medical cannabis market. iAnthus earlier acquired roughly 6 percent of GrowHealthy in a preferred share purchase in October 2017.

iAnthus Capital Holdings, Inc. (ITHUF), closed Monday's trading session at $4.42, up 7.28%, on 885,098 volume with 1,587 trades. The average volume for the last 60 days is 178,320 and the stock's 52-week low/high is $1.325/$4.14.

Rhino Resource Partners LP (RHNO)

Marketbeat, TopPennyStockMovers, Wall Street Mover, and PCG Advisory reported previously on Rhino Resource Partners LP (RHNO), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Rhino Resource Partners LP is a diversified energy limited partnership based in Lexington, Kentucky. It concentrates on coal and energy related assets and activities. This includes energy infrastructure investments. Rhino is a diversified energy MLP (Master Limited Partnership). It produces coal in manifold basins in the United States Rhino Resource Partners lists on the OTC Markets’ OTCQB.

The Company produces metallurgical and steam coal in a variety of basins across the U.S. Moreover, Rhino leases coal via its Elk Horn subsidiary. The Company’s strategy is to acquire coal reserves and properties with relatively long lives and that could undergo development with low risk at a reasonable cost.

Rhino Resource Partners produces steam coal used to generate electricity and metallurgical coal used in the steel-making process. Additionally, Rhino manages and leases coal properties and collects royalties from such management and leasing activities. The Company also has oil and gas investments in the Cana Woodford region, which provides added cash flows to its business.

Through acquisitions and other coal lease transactions, Rhino Resource Partners has significantly increased its proven and probable coal reserves and non-reserve coal deposits. In addition, the Company has successfully grown its coal production by way of internal development projects.

In December of 2016, Rhino Resource Partners announced that it entered into an option agreement with Royal Energy Resources, Inc. (ROYE), Rhino Resource Partners Holdings, LLC (Rhino Holdings), an entity wholly-owned by certain investment partnerships managed by Yorktown Partners LLC, and Rhino GP LLC, the general partner of Rhino. Rhino received an option (Call Option) from Rhino Holdings to acquire substantially all of the outstanding common stock of Armstrong Energy, Inc. currently owned by investment partnerships managed by Yorktown.

The Option Agreement specifies that Rhino can exercise the Call Option no earlier than January 1, 2018, and no later than December 31, 2019. In exchange for Rhino Holdings granting Rhino the Call Option to purchase Armstrong Energy, the Partnership issued 5.0 million new common units (Call Option Premium Units) to Rhino Holdings upon the execution of the Option Agreement.

This past November, Rhino Resource Partners announced that it closed an agreement with a third party to transfer 100 percent of the memberships interests and related assets and liabilities in the Partnership’s Sands Hill Mining LLC entity to the third party in exchange for a future override royalty for any mineral sold, excluding coal, from Sands Hill after the closing date.

The third party assumed the surface coal mining operations and the limestone operations at Sands Hill. The Partnership maintained ownership of an Ohio River barge loading facility, which was previously owned and operated by the Sands Hill entity. The Partnership’s belief is that this asset can provide considerable value to Rhino Resource Partners via the sale or potential lease of the facility.

Rhino Resource Partners LP (RHNO), closed Monday's trading session at $3.05, up 1.33%, on 2,692 volume with 13 trades. The average volume for the last 60 days is 2,796 and the stock's 52-week low/high is $1.10/$5.99.

Real Goods Solar, Inc. (RGSE)

InvestorsHub, Investor Place, Stock News Gazette, Stock Twits, MarketWatch, Barchart, and TradingView reported on Real Goods Solar, Inc. (RGSE), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Real Goods Solar, Inc.’s RGS Energy operates as a residential and small business commercial solar energy engineering, procurement, and construction company in the United States. The Company has installed greater than 25,000 solar energy systems for homes, businesses, schools, government facilities, and utilities throughout the nation. This has totaled over 260 megawatts of clean energy. Real Goods Solar (RGS Energy) is based in Denver, Colorado. RGS Energy is the Company’s registered trade name.

Additionally, the Company is the exclusive manufacturer of POWERHOUSE™. This is an inventive in-roof solar shingle utilizing technology developed by The Dow Chemical Company. RGS Energy entered into an exclusive domestic and worldwide license agreement with The Dow Chemical Company for the POWERHOUSE™ solar shingles system. RGS will lead all commercial activities for the product. This includes supply chain management, marketing, sales, installation, as well as warranty.

This solar shingle system has been installed on greater than 1,000 homes. RGS Energy and Dow Chemical anticipate UL product certification during Q1 of 2018. Pre-orders are being taken in advance of final written certification. RGS Energy’s plan is to begin sales and installation of POWERHOUSE™ 3.0 solar shingles immediately after.

Regarding RGS Energy’s business segments, the Solar Division consists of RGS Energy’s Residential and Sunetric business segments. The Corporate segment includes administrative costs associated with administrative services, legal settlements, legal, information systems, and accounting and finance. Beginning on September 29, 2017, POWERHOUSE™ is the Company’s new business segment.

This past November, RGS Energy announced the on-time launch of Solar 365™. This is the Company’s new mobile software and online dashboard suite. New and prospective customers can easily navigate Solar 365™. They can access information and documents concerning their planned solar installation wherever and whenever it is convenient. After installation, customers can easily access and view their cost savings and production stats in kilowatts and dollars earned if net metering.

In 2017, RGS Energy was chosen as exclusive installer for the Solarize Cranston, Solarize Granby, Solarize New Haven and Solarize North Haven communities.

For 2018, RGS Energy expects to attain UL Certification during Q3 and commence sales and installation of POWERHOUSE™ 3.0 solar shingles afterwards. Regarding its Solar Division, RGS Energy expects to realize break-even revenue, apart from POWERHOUSE™, in Q3.

Real Goods Solar, Inc. (RGSE), closed Monday's trading session at $1.15, up 0.88%, on 176,694 volume with 453 trades. The average volume for the last 60 days is 714,778 and the stock's 52-week low/high is $0.6001/$7.20.

ProMIS Neurosciences, Inc. (ARFXF)

Streetwise Reports and OTC Markets reported on ProMIS Neurosciences, Inc. (ARFXF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A development stage biotechnology enterprise, ProMIS Neurosciences, Inc. concentrates on discovering and developing precision medicine therapeutics to treat neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). ProMIS Neurosciences has offices in Toronto, Ontario and Cambridge, Massachusetts. The Company’s shares trade on the OTC Markets Group’s OTCQB.

ProMIS Neurosciences’ proprietary target discovery engine is founded on the use of two complementary techniques. ProMIS applies its thermodynamic, computational discovery platform-ProMIS™and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Utilizing this innovative precision medicine approach, the Company is developing novel antibody therapeutics and specific companion diagnostics for AD and ALS.

The Company’s lead programs are following a “best in class” strategy targeting Amyloid beta in Alzheimer’s disease, with advantages over ”first in class” therapy from Biogen (aducanumab). ProMIS uses its proprietary technology platform to create highly selective antibodies.

ProMIS Neurosciences’ lead product is PMN310 in Alzheimer’s disease. It is on course to further confirm differentiation from likely “first in class” Biogen’s aducanumab. In addition, it is on course to initiate clinical trials in 2019 and potentially superior clinical data in comparison to aducanumab in late 2021 shortly after aducanumab anticipated approval.

For Alzheimer’s disease, ProMIS Neurosciences’ most advanced priority program, three validated product candidates have been designated. These are PMN310, PMN350, and PMN330.

Earlier this month, ProMIS Neurosciences announced that its lead product candidate for Alzheimer's disease (AD), PMN310, showed absence of binding to amyloid beta (Aβ) plaque in and around blood vessels in AD brain samples in a preclinical study directly comparing PMN310 to other Aβ-directed antibodies.

Binding of therapeutic antibodies to Aβ deposits in brain tissue, more specifically blood vessels, is believed to underlie the development of ARIA (amyloid-related imaging abnormalities; brain swelling and microhemorrhages) in treated AD patients.

ProMIS Neurosciences’ President and Chief Executive Officer, Mr. Elliot Goldstein, MD, stated: "PMN310 was designed to selectively target the toxic, prion-like Aβ oligomers, now widely believed to be a root cause of AD. By not targeting Aβ plaque, especially in and around blood vessels in the brain, we anticipate PMN310 may not be associated with the dose-limiting brain swelling seen with plaque-binding antibody therapeutics like aducanumab. Confirmation of such an improved safety profile in clinical trials would allow for administration of higher doses to AD patients, thereby leading to greater therapeutic potency of PMN310."

ProMIS Neurosciences, Inc. (ARFXF), closed Monday's trading session at $0.4198, up 48.60%, on 8,491,835 volume with 2,326 trades. The average volume for the last 60 days is 149,058 and the stock's 52-week low/high is $0.1103/$0.70.

RealBiz Media Group, Inc. (RBIZ)

HotStockProfits, PennyDoctor, Pumps and Dumps, Value Penny Stocks, Beacon Equity Research, InvestorSoup, Penny Stock Craze, Penny Stocks Finder, Stock Preacher, Stock Roach, StockHideout, Stock Commander, Juicy Penny Stocks, Wallstreet Profiler, DSR News, Trading Wall St, Ascending Stocks, SmallCapVoice, TopPennyStockMovers, Fortune Penny Stocks, and SuperStockTips, 007 Stock Chat, and PennyStockSpy reported on RealBiz Media Group, Inc. (RBIZ), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

RealBiz Media Group, Inc. operates two business segments. One is a worldwide food subsidiary (Verus Foods), which sells products to customers internationally. The other is a real estate digital media and technology company. RealBiz Media Group is headquartered in Gaithersburg, Maryland.

The Company helps real estate agents and brokerages build their online visibility, connect with customer prospects, and turn those prospects into new customers. RealBiz has in place exclusive agreements with key players such as Century21 and ERA systems. The RealBiz video platform is built on 20 patents and developed completely in-house over 10 years. It is the premier video technology platform for high speed, high quality video production.

RealBiz Media’s Verus Foods markets under its own brand mainly to supermarkets, hotels, and other members of the wholesale trade. Verus Foods’ initial focus is on frozen foods, specifically meat, poultry, seafood, vegetables, and French fries.

Verus has a major regional presence in the Middle East and North Africa (MENA) and sub-Saharan Africa (excluding Office of Foreign Assets Control (OFAC)-restricted nations). Verus Foods has deep roots in the Gulf Cooperation Council (GCC) nations.

Pertaining to RealBiz Media’s proprietary video processing technology, it makes it one of the leaders in providing home video tours to the real estate industry. The Company’s customer base includes more than 350,000 real estate agents and brokers.

RealBiz has access to the nation’s largest real estate companies with many approved vendors and national contracts. Its strength is centered on its proprietary video production and distribution technology.

RealBiz provides a series of products. This includes a consumer website (www.nestbuilder.com), an agent-only platform called Nestbuilder Agent 2.0, an agent social media and marketing solution, a growing microvideo app (MVA) network, virtual tours, and mobile apps. The Company’s proprietary technology allows the automated conversion of data, including text and pictures of home listings, into video with voice and music. Upon creation, the videos can automatically be distributed to numerous media platforms for consumer viewing.

In September 2017, RealBiz Media Group announced that it signed an agreement with The Walt Disney Company to become the exclusive distributor of Disney-branded juice products in the United Arab Emirates (UAE) and Oman.

With this deal deal, Verus Foods becomes the exclusive distributor of juice products bearing Disney and Pixar characters and other Disney labels in these Gulf Cooperation Council (GCC) nations.

RealBiz Media Group, Inc. (RBIZ), closed Monday's trading session at $0.0025, down 10.71%, on 5,089,372 volume with 32 trades. The average volume for the last 60 days is 1,742,425 and the stock's 52-week low/high is $0.0021/$0.045.


The QualityStocks
Company Corner


MGX Minerals Inc. (MGXMF)

The QualityStocks Daily Newsletter would like to spotlight MGX Minerals Inc. (MGXMF). Today, MGX Minerals Inc. closed trading at $1.47, up 5.76%, on 850,613 volume with 598 trades. The stock’s average daily volume over the past 60 days is 218,218 and its 52-week low/high is $0.543/$2.119.

MGX Minerals Inc. (CSE:XMG) (FKT:1MG) (OTCQB:MGXMF) is pleased to report that joint venture partner Power Metals Corp. (“Power Metals”) has completed initial drilling and intersected lithium mineralization on the Northeast Dyke at the Case Lake Property in Ontario (see figure 1). The Winter 2018 drill program is in its early stages and the presence of up to 30% coarse grained spodumene in drill core has been found in several of the first few holes. The first samples have been shipped to SGS preparation lab in Cochrane, Ontario. Due to this occurrence, Power Metals has increased its current drill program from 2000m to 3000m.

MGX Minerals Inc. (CSE: XMG) (FKT: 1MG) (OTCQB: MGXMF) is a diversified Canadian resource company developing large-scale mineral portfolios in specific commodities and jurisdictions in North America. The company controls significant interest in lithium, magnesium and silicon assets that offer streamlined development timelines and low capital expenditures. MGX Minerals and its engineering partner have developed a patent-pending, low-energy design process to extract valuable minerals from the abundant, highly mineralized brine wastewater produced each year by oil and gas companies.

This proprietary, petrolithium process rapidly concentrates lithium and other minerals from brine in less than a day. That's a stunning advancement from the conventional method of extracting minerals from brine through an evaporation process that can take up to 18 months, requires hundreds of acres of land, and averages less than a 50 percent mineral recovery rate. Using this advanced water purification technology, MGX Minerals cleans the wastewater that accompanies petroleum as it's being pulled up to the surface. The company's petrolithium process eliminates the need to inject contaminated wastewater back into the ground, which prevents drinking water contamination and possible earthquakes.

In January 2017, MGX Minerals successfully recovered concentrated lithium from heavy oil evaporator blowdown wastewater using its rapid recovery process, an accomplishment independently confirmed by the Saskatchewan Research Council. In August 2017, the company also successfully processed wastewater and lithium brine from eight North American projects at its one-cubic-meter-per-hour processing plant, proving the technology is economically viable. Research group Global Water Intelligence expects the wastewater treatment industry to grow into a $45 billion market annually by 2025, which suggests there are ample revenue-generating opportunities for MGX Minerals technology.

Lithium, the "white gold" of the new energy economy, is the key to clean energy development as global demand for hybrid and electric vehicles, high-drain portable electronic devices, and large-scale energy storage systems ramps up. Grand View Research, Inc. reports that the global lithium-ion battery market is expected to reach $93.1 billion by 2025. Current market forces show a high demand for lithium and a low supply, which further supports the necessity of MGX Mineral's cleaner, faster method of extracting high-value minerals from brine wastewater.

MGX Minerals is led by a team of industry standout performers who have worked in the mining and technology industries for decades. The leadership team is joined by an array of top-notch technical partners with unmatched experience in the oil and gas sectors, environmental services industry, marketing and product development, along with applied research and commercial development of technologies. Disclaimer

MGX Minerals Inc. Blog

MGX Minerals Inc. News:

MGX Minerals Announces Spodumene Mineralization Intersected on New Northeast Dyke at Case Lake; Drill Program Increased to 3,000 metres

MGX Minerals Announces 2.07 % Li2O and 213.96 ppm Ta Over 18.0 m at Case Lake

MGX Minerals Partners with Highbury Energy to Extract Nickel, Vanadium, and Cobalt from Petroleum Coke

Tapinator, Inc. (TAPM)

The QualityStocks Daily Newsletter would like to spotlight Tapinator, Inc. (TAPM). Today, Tapinator, Inc. closed trading at $0.4305, up 7.63%, on 361,427 volume with 136 trades. The stock’s average daily volume over the past 60 days is 255,418 and its 52-week low/high is $0.0711/$0.72.

Tapinator, Inc. (OTCQB: TAPM), a leading developer and publisher of mobile games on the iOS, Google Play, Amazon, and Ethereum platforms, today announces that it is sponsoring and will speak on a panel at leading blockchain conference, ETH Denver on February 17th. The panel will focus on the intersection of blockchain & gaming and the Company will announce it first blockchain product, which will be released by Tapinator's subsidiary, Revolution Blockchain, in Q2 of this year.

Tapinator, Inc. (TAPM) is a developer and publisher of mobile games on the iOS, Google Play and Amazon platforms. The Company's portfolio includes over 300 mobile gaming titles generating hundreds of thousands of daily player downloads that provide predictable and attractive returns through the sale of branded advertisements and consumer app store transactions. Tapinator, based in New York and with product development teams located throughout the world, was founded in 2013 by a visionary team that has been building mobile games and applications since 2007 and has achieved multiple successful exits.

Tapinator's business strategy includes the creation of a select number of best-in-class Full-Featured Games, such as ROCKY™ and Solitaire Dash, which provide game players with more in-depth, unique content that supports long-term retention and generates higher investment returns. The Full-Featured Games model creates the potential for sustainable $100+ million franchise-type games that have product lifespans of at least five years. Tapinator uses a proprietary set of dynamic development and marketing processes factored upon gaming category, estimated player retention and projected player profitability.

Recent successful launches of two new Full-Featured titles – Big Sport Fishing 2017 and Dice Mage 2 – were recognized on the Apple iOS platform as "New Games We Love." During the game's first seven days after global release, Big Sport Fishing 2017 received well over 520,000 player downloads. Four new titles, ColorFill, Divide & Conquer, Shadowborne and Fusion Heroes, are in the pipeline for release in Q4 2017 and Q1 2018 as well. The formula for these game combines proven gameplay elements with best-in-class monetization systems, supplemented by Tapinator's strong creative team of developers, strategists and product specialists. The company's Rapid-Launch Games division also saw increasing player interest recently with the launch of Fidget Spinner Superhero and Scary Shark Evolution 3D.

Tapinator's diversified revenue sources includes 54 percent from advertising placed within its mobile games and 46 percent from consumer app store purchases. The Company limits advertising placements to between game levels and also runs rewarded video ad units that are tied directly into the game's currency. Tapinator's portfolio includes more than 300 active titles, with no single game accounting for more than 25 percent of total revenues during the first half of 2017.

As Tapinator looks toward the future, opportunities in Virtual Reality (VR) and Augmented Reality (AR) show great promise. The company has released several prototype VR games to gather data before pursuing a more significant VR product. Recent market reports suggest that the VR industry will hit $30 billion by 2020 and the AR industry will surpass that with a projected $120 billion. Tapinator also plans to pursue publishing transactions that leverage its network, platform relationships and operational excellence. Significant opportunities for expanding Tapinator's gaming IP to new platforms such as Steam and leading messaging apps are also on the horizon. The company is targeting a 30+ percent annual bookings growth target for 2017-2019. Disclaimer

Tapinator, Inc. Blog

Tapinator, Inc. News:

Tapinator to Make Product Announcement at Leading Blockchain Conference

Blockchain Emerging as a New Frontier for the Gaming Industry

Tapinator Introduces New Subsidiary Focused on Decentralized Blockchain Apps

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.0406, up 0.12%, on 3,580,182 volume with 242 trades. The stock’s average daily volume over the past 60 days is 13,484,475, and its 52-week low/high is $0.009/$0.16.

Global Payout, Inc. (OTC Pink:GOHE) ("the Company") is pleased to announce that, despite initial delay, the official initiation of the formal audit will likely begin at the start of February, and make way for the filing of the form 10-K sometime in March. This progress signifies that the Company has made great strides in developing a strong base from which to build competitive subsidiaries in several key market sectors.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

Global Payout Inc. Announces Launch of Official Audit in February 2018, Form 10-K to Follow in March

MoneyTrac Technology, Inc. Establishes Joint Venture Partnership with Crypto Value Management System, LLC

Global Payout, Inc. Launches Supply Chain Finance Logistics Subsidiary - SecurCapital Corp.


The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $2.40, up 18.81%, on 1,221,143 volume with 1,604 trades. The stock’s average daily volume over the past 60 days is 602,401 and its 52-week low/high is $0.6171/$2.3064.

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:

ABcann Granted Australian Import License

ABcann Appoints New Chief Marketing Officer

ABcann Global Announces Receipt of Health Canada License to Produce Cannabis Oils

AnalytixInsight Inc. (TSX.V:ALY) (OTCQB:ATIXF)

The QualityStocks Daily Newsletter would like to spotlight AnalytixInsight Inc. (ATIXF). Today, AnalytixInsight Inc. closed trading at $0.5429, up 14.29%, on 9,800 volume with 8 trades. The stock’s average daily volume over the past 60 days is 38,040 and its 52-week low/high is $0.15/$0.6898.

AnalytixInsight Inc. (TSX.V: ALY) (OTCQB: ATIXF) is an artificial intelligence (AI) company that transforms data into knowledge. The company has developed a proprietary, machine-learning technology that algorithmically analyzes big data and distills it into actionable insights. AnalytixInsight has strategic initiatives in fintech, blockchain and workflow analytics, and its technology is scalable and extendable to virtually any data-driven industry such as sports, communications, healthcare, insurance or government.

The company's flagship product – CapitalCube.com – is a financial portal providing comprehensive company analysis including on-demand fundamental research, portfolio evaluation and screening tools on over 50,000 global equities and North American ETFs. CapitalCube's online portal is designed to empower investment ideas by providing in-depth analysis, peer-to-peer performance evaluations, accounting and earnings reports, dividend strength and AI-supported information about likely corporate actions such as dividend changes, share buybacks and acquisitions. AnalytixInsight provides a robust technology that is frequently rebalanced to maintain a desired risk profile, matching risk to ideal ETF exposure, with regular compliance reporting.

CapitalCube's freemium pricing model allows free access to basic financial information, with additional in-depth analysis and predictive analytics provided at a rate of $25 per month, and customized peer analysis for $300 per month. CapitalCube publishes 3,000 articles daily and has multi-language capabilities. Thomson Reuters and Africa Investor have recently been added to the growing network of content partnerships that already includes Euronext NV, Yahoo Finance and The Wall Street Journal.

Euclides Technologies is a subsidiary company focused on Field Service Management software solutions, led by a team with decades of experience in developing and implementing workforce management solutions for large global corporations. With worldwide customers representing over 100,000 field service personnel across multiple industries, Euclides Technologies has a deep understanding of the increasing amount of data generated within the industry, as well as the analytics solution offerings to transform that data into knowledge.

MarketWall is a Fintech subsidiary that develops integrated software solutions as part of an ecosystem of smart devices that includes PCs, tablets, smart phones, wearable mobile devices and Smart TV. AnalytixInsight Inc. has joint ownership in MarketWall together with Intesa Sanpaolo, Italy's largest retail bank which has over 4,000 branches and a market capitalization of $40 billion Euros. MarketWall is expected to deploy its real-time stock trading and mobile banking app to Intesa Sanpaolo's 12.6 million customers in six European countries during 2018. The mobile stock trading application will directly interface with Intesa Sanpaolo's established MarketHub trading platform. As a Samsung Global Partner, the MarketWall app is preloaded in mobile devices in certain areas in Europe.

AnalytixInsight is currently evaluating and pursuing Blockchain initiatives which are contiguous with its artificial intelligence platform, to use a distributed ledger technology to reduce transaction costs and settlement times for its users, partners, and subsidiaries. The Company believes these initiatives will enhance current revenues being received from existing multi-year agreements with its partners. Disclaimer

AnalytixInsight Inc. Blog

AnalytixInsight Inc. News:

NetworkNewsBreaks – AnalytixInsight, Inc. (TSX.V: ALY) (OTCQB: ATIXF) Featured on BNN’s Market Call

AnalytixInsight Inc. Reports Record Revenues for Third Quarter and First Operating Profit

AnalytixInsight, Inc. (TSX.V: ALY) (OTCQB: ATIXF) Enhances Artificial Intelligence Platform, Generating Impressive Growth

Grey Cloak Tech, Inc. (GRCK)

The QualityStocks Daily Newsletter would like to spotlight Grey Cloak Tech, Inc. (GRCK). Today, Grey Cloak Tech, Inc. closed trading at $0.0034, up 9.68%, on 8,348,038 volume with 95 trades. The stock’s average daily volume over the past 60 days is 9,692,600 and its 52-week low/high is $0.0027/$0.1499.

Grey Cloak Tech, Inc. (OTCQB: GRCK), a Las Vegas, Nevada-based company, aims to expand into the rapidly growing cannabinoid (CBD) market through the pending acquisition of Eqova Life Sciences, which focuses on providing a full spectrum line of clinical-grade hemp oil (CBD) products to the medical practitioner market. Eqova Life Sciences, based in Denver, Colorado, develops its own high quality, branded product line of hemp oil health products, with the offer of producing private labels to qualified partners.

Eqova Life Sciences recently exhibited the company's CBD products at the Integrative Medicine Summit in Denver, Colorado, which was attended by over 200 medical professionals. As part of the exhibition, Eqova Life Sciences also debuted its new CannaBio Salve, an innovative topical salve infused with several aromatic natural oils. The company's formulations combine the scientifically-validated, powerful benefits of cannabinoids in standardized products which are then distributed to patients under the care of qualified health practitioners. All Eqova products are carefully researched and go through rigorous third-party testing before and after marketing, providing the security of a clinical-grade product made in cGMP Compliant Labs located in the United States.

According to The Hemp Business Journal, the CBD products marketplace is projected to grow 700 percent by 2020 with annual sales reaching $2.1 billion. The purchase of Eqova Life Sciences would be a natural fit for the company, which has been looking for a way to build shareholder value by adding acquisitions from the rapidly growing CBD sector. Grey Cloak Tech believes medical practitioners seeking high-quality CBD products represent a vastly underserved market. To date, no other hemp oil company has exclusively focused on providing clinical-grade, full-spectrum hemp oil products to this important segment of the medical community.

Grey Cloak Tech also develops advanced software to overcome costly digital threats, most commonly known as online fraud. Grey Cloak Tech leads the industry with continuous development of the most comprehensive and effective weapons against online security threats. The company's proprietary digital advertising fraud detection software, Fraudlytic, provides a cloud-based, secure platform that monitors Internet traffic in real time, blocking malicious and false clicks, while allowing real consumers to view offers and make purchases. Disclaimer

Grey Cloak Tech, Inc. Blog

Grey Cloak Tech, Inc. News:

Grey Cloak (OTCQB: GRCK) Announces Strategic Partnership With Canbiola, Inc

Grey Cloak Announces the Launch of CBD TV

Grey Cloak Announces the Launch of CBD.co — “The Cannabinoid Marketplace”

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF). Today, PreveCeutical Medical Inc. closed trading at $0.35, up 7.69%, on 100 volume with 1 trade. The stock’s average daily volume over the past 60 days is 408, and its 52-week low/high is $0.01/$0.70.

PreveCeutical Medical Inc. (PRVCF), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word "PreveCeutical" – a combination of the words "preventive" and "pharmaceutical" – was a precursor to the company's formation and incorporation in October 2015.

The company's first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical's research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical's gene-silencing technology would effectively "turn off" the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical's science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland's (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.'s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company's core. Disclaimer

PreveCeutical Medical Inc. Company Blog

PreveCeutical Medical Inc. News:

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is “One to Watch”

PreveCeutical Announces Amendment to $3.28 Million Non-Brokered Private Placement

PreveCeutical Medical Inc. Announces $3.28 Million Fully Subscribed Private Placement


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



CNBC Breaking News
(BIVV) +61.89%


Trader Power News
(LTBR) +57.82%


(FRLF) +54.33%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251